期刊
BIOMATERIALS
卷 86, 期 -, 页码 83-91出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2016.01.056
关键词
Protein nanoparticle; T cells; CD8; Biomimetic; Tumor-associated antigen; Vaccine
资金
- National Institutes of Health [R21EB017995]
- National Cancer Institute of the National Institutes of Health [P30CA062203]
- University of California Cancer Research Coordinating Committee [UCCRCC-101868]
The immune system is a powerful resource for the eradication of cancer, but to overcome the low immunogenicity of tumor cells, a sufficiently strong CD8(+) T cell-mediated adaptive immune response is required. Nanoparticulate biomaterials represent a potentially effective delivery system for cancer vaccines, as they can be designed to mimic viruses, which are potent inducers of cellular immunity. We have been exploring the non-viral pyruvate dehydrogenase E2 protein nanoparticle as a biomimetic platform for cancer vaccine delivery. Simultaneous conjugation of a melanoma-associated gp100 epitope and CpG to the E2 nanoparticle (CpG-gp-E2) yielded an antigen-specific increase in the CD8(+) T cell proliferation index and IFN-y secretion by 1.5-fold and 5-fold, respectively, compared to an unbound peptide and CpG formulation. Remarkably, a single nanoparticle immunization resulted in a 120-fold increase in the frequency of melanoma epitope-specific CD8(+) T cells in draining lymph nodes and a 30-fold increase in the spleen, relative to free peptide with free CpG. Furthermore, in the very aggressive B16 melanoma murine tumor model, prophylactic immunization with CpG-gp-E2 delayed the onset of tumor growth by approximately 5.5 days and increased animal survival time by approximately 40%, compared to PBS treated animals. These results show that by combining optimal particle size and simultaneous co delivery of molecular vaccine components, antigen-specific anti-tumor immune responses can be significantly increased. (C) 2016 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据